Bluejay Diagnostics

Bluejay Diagnostics, Inc. operates as a diagnostic company. It develops and markets minimally-invasive Point-of-Care diagnostics tests and devices that provide patients and providers with access to affordable and timely healthcare. It focus is on the infectious disease, inflammation, and oncology markets. The company was founded by Svetlana Dey and Dey Indraneil on March 20, 2015 and is headquartered in Acton, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACTON, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that Kenneth Fisher, CPA, has joined the Company as Chief Financial Officer (CFO), effective March 23, 2022. He will report to Neil Dey, Chief Executive Officer. Gordon Kinder resigned his position as CFO to pursue other professional interests.

Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer

Butterfly Network

Clover Health Investments

Hall of Fame Resort & Entertainment

Skillz

Penny stocks to buy according to insiders this week. The post Best Penny Stocks For March 2022?

Best Penny Stocks For March 2022? 5 To Watch With Insider Buying

Testing program underway for lead product candidate, the Symphony IL-6 Test, in support of an FDA Marketing Application, planned for Q3 2022

Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

The stock price of Bluejay Diagnostics, Inc. (NASDAQ: BJDX) increased by over 17% pre-market today. This is why it happened.

Bluejay Diagnostics (BJDX) Stock: Why The Price Jumped Up Today

ACTON, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that it has filed a Pre-Submission package for the Symphony IL-6 Test with the U.S. Food and Drug Administration (“FDA” or “the agency”). The purpose of this filing is to request feedback from the agency prior to submitting a medical device marketing application. The pre-submission package will allow the FDA to review and comment on the Company's plans for clinical trials and analytical testing.

Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA

This Study performs unique rapid on-site measurement using patient whole blood and positions Company to move forward with multiple initiatives This Study performs unique rapid on-site measurement using patient whole blood and positions Company to move forward with multiple initiatives

Bluejay Diagnostics, Inc. Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19 Patients in Critical Care

Immix Biopharma

Ocugen, Inc.

Here are three penny stocks to add to your watchlist right now The post Check These 3 Penny Stocks Out For Your Morning Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check These 3 Penny Stocks Out For Your Morning Watchlist

HeartBeam

Blackboxstocks

Bridgeline Digital

China Liberal Education Holdings 

Data Storage Corp

G Medical Innovations Holdings Ltd

Lucid Diagnostics

NeuroBo Pharmaceuticals Inc

Nxt-ID

If you're willing to absorb massive risk for the chance of significant upside, these low-float penny stocks could fit the bill. The post 10 Low-Float Penny Stocks for Steel-Gutted Investors appeared first on InvestorPlace.

10 Low-Float Penny Stocks for Steel-Gutted Investors

ACTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced the appointment of Mark W. Feinberg, M.D. as Chief Medical Advisor. Dr. Feinberg will guide Bluejay's clinical development programs and provide strategic medical and scientific leadership to the Company.

Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor

IL-6 test for sepsis triage on Track for January 2022 FDA Pre-Submission Filing

Bluejay Diagnostics, Inc. Reports Third Quarter 2021 Financial Results

 Orbital Energy Group, Inc.

Reliance Global Group

Tivic Health Systems

The stock market is down today but these penny stocks are rallying. The post 4 Top Penny Stocks To Watch With The Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Top Penny Stocks To Watch With The Stock Market Down Today

Bit Brother Ltd

BeyondSpring

Invacare

NuZee, Inc.

OPKO Health

PetVivo Holdings

Petros Pharmaceuticals

Ring Energy

Spectrum Pharma

Looking for potential short squeeze penny stocks? Start by looking at short interest The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 10 Short Squeeze Stocks To Watch

ACTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage, diagnosis and monitoring of disease progression, today announced the pricing of an underwritten Initial Public Offering of 2,160,000 units, at a combined price per unit of $10.00, consisting of:

Bluejay Diagnostics, Inc. Announces Pricing of Upsized $21.6 Million Initial Public Offering

News for Bluejay Diagnostics Stock (BJDX)